Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Azilsartan Medoxomil Co-administered with Chlorthalidone in Essential Hypertension
NCT00591773Phase 3Completed
- Sponsor
- Takeda
- Start
- Sep 2007
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azilsartan medoxomil in essential hypertension (3 arms), sponsored by Takeda. Primary endpoint: Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring at 6 weeks. Started Sep 2007; status: completed.
02
Drugs
azilsartan medoxomil
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00591773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00591773.